K002095

MAR - 2 2001

EXHIBIT 2

Snap Laboratories, LLC
3633 West Lake Avenue Suite 406
Glenview, IL 60025 USA
847-657-8100
Fax: 847-657-8105
Contact Name:
Gil Raviv, President
July 9, 2000

510(k) Summary of Safety and Effectiveness

1. Identification of the Device

Proprietary-Trade Name: "Snap Model 6TM"

Classification Name: MNR Apnea/Snoring Recording and analysis Device and DQA, Oximeter.

Added sensors for the modification: BZQ and LXJ

Common/Usual Name: Snoring and Apnea Recording and Analysis Device

- 2. Equivalent legally marketed devices This product is similar in design and function to the "Digi-Snap TM (Snap Model 4)" Testing Device
- 3. The intended use of the "Snap Model 6TM" device is to screen patients for apnea and snoring and to provide quantitative and qualitative analysis of apnea and snoring. The "Snap Model 6TM" testing system is only intended for short term monitoring such as to record the oximetry and snoring sounds continuously during the night. The system is not intended as a substitute for full polysomnography when additional parameters such as sleep stages, limb movements or EEG activity are required. The target population is patients who are suspected of apnea and/or complain about snoring. The majority of the screenings are going to take place at the patient's home, although some may take place in a sleep laboratory. Both pediatric and adult patients may be tested. CAUTION: US Federal law restricts this device to sale by or on the order of a physician, Use of this device must be under the direct supervision of a qualified adult (parent or guardian) or health care practitioner trained in the use of the "Snap Model 6TM" device.
- 4. Description of the Device: This notification is for a <u>modification</u> to the existing device, the "Digi-SnapTM" (Snap Model 4) Testing Device. The modified device is called the "Snap Model 6TM" The modification involves the use of the already present analog/digital converter channels for (1) Respiratory Effort, (2) Limb Movement, and (3) Body Position (4) Spare.
- 5. Safety and Effectiveness, comparison to predicate device. The results of bench and user testing indicates that the modified device is as safe and effective as the predicate device. The modified device is easy for the user to set up at home or in the sleep laboratory. The modification involves the use of additional channels to acquire and display more information about the patient during sleep, as noted above. An oximeter is connected to the unit along with the usual microphone/cannula apparatus and the oximeter sensor is slipped over the patient's finger in the usual manner. The additional sensors for (1) Respiratory Effort, (2) Limb Movement, and (3)

Body Position are attached to the patient

6. The patient turns on the unit, then goes to sleep. Apnea and snoring events are then recorded. After awakening, the patient returns the disk and the equipment to the analysis service center, where the disk is analyzed.

7. Substantial Equivalence Chart

Characteristic	Predicate device: Digi- SNAP TM (Snap Model 4 TM)	Modified device: "Snap Model 6 TM "
Labeling:	testing device K984169 (Original submission)	The labeling has been updated to show the use of the additional sensors.
Intended Use:	Recording and analysis of snoring and apnea	Same
Physical characteristics:		
Recording device:	100 MB "Zip" Drive and proprietary interface.	Same.
Channels acquired:	Snoring sounds, Oximetry level, and pulse	Snoring sounds, Oximetry level, pulse, respiratory effort, limb movement, and body position.
User equipment:	Zip unit, Zip Disk, cannula, microphone, and oximeter: Nonin OEM II or Xpod.	Zip unit, Zip Disk, cannula, microphone, and oximeter: Nonin OEM II, plus respiratory effort, limb movement, and body position sensors
Energy Source:	90-240 V, 50/60~ internal Medical grade power supply	Same
Anatomical sites:	Upper lip and finger probe	Same plus respiratory effort, limb movement, and body position sensors
Performance testing:	Summarized above	Same
Safety characteristics:		
Electrical safety:	Per applicable sections of UL-2601	Same
EMI:	Per FCC part 15 Class B	Same
Oximetry	Included	Same
Intended population	Adults and pediatrics	Same
Home use	Yes	Same

7. Conclusion

After analyzing both bench and user testing data, it is the conclusion of Snap Laboratories that the "Snap Model 6TM" testing snoring and apnea testing device is as safe and effective as the predicate device and has no new indications for use, thus rendering it substantially equivalent to the predicate Snap Testing Device.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR - 2 2001

Gil Raviv, Ph.D. President Snap Laboratories, LLC 3633 West Lake Avenue Suite 406 Glenview, IL 60025

Re: K002095

Trade Name: Snap Model 6 Regulatory Class: II (two) Product Code: MNR

Dated: November 29, 2000 Received: December 05, 2000

Dear Dr. Raviv:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

James E. Dillard III

Director

Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

SNAP® Laboratories

Sleep Apnea & Snoring Analysis

3633 West Lake Ave., Suite 406 - Glenview, IL 60025 Phone: 800 SNAP 786 Fax: 847-657-8105

i) Indications for Use

510(k) Number 600095

Device Name: "Snap Model 6TM" Snoring and Apnea recording and analysis system

Indications for Use:

The "Snap Model 6TM" device is indicated for use in the diagnostic evaluation of patients for apnea and snoring and to provide quantitative and qualitative analysis of apnea and snoring.

The "Snap Model 6TM" testing system—is not intended as a substitute for full polysomnography when additional parameters such as sleep stages or EEG activity are required.

The target population is patients who are suspected of apnea and/or complain about snoring. The majority of the testings are going to take place at the patient's home, although some may take place in a sleep laboratory. Both pediatric and adult patients may be tested.

CAUTION: US Federal law restricts this device to sale by or on the order of a physician, Use of this device must be under the direct supervision of a qualified adult (parent or guardian) or health care practitioner trained in the use of the "Snap Model 6TM" device.

Concurrence of CDRH, Office of Device Evaluation (ODE)

Division of Cardiovascular & Respiratory Devices 510(k) Number

Prescription Us

Over the Counter Use

(Per 21 CFR 801.109)